亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

富维斯特朗 帕博西利布 医学 肿瘤科 内科学 转移性乳腺癌 临床终点 阿那曲唑 无进展生存期 癌症 乳腺癌 随机对照试验 化疗 雌激素受体 三苯氧胺
作者
Erica L. Mayer,Yue Ren,Nikhil Wagle,Reshma Mahtani,X. Cynthia,Angela DeMichele,Massimo Cristofanilli,Jane Meisel,Kathy D. Miller,Trevor A. Jolly,Elizabeth Riley,Rubina Qamar,Helga B. Salvesen,Sonya Reid,Natalie Sinclair,Meredith Faggen,Caroline Block,Naomi Y. Ko,Ann Partridge,Wendy Y. Chen,Michelle K. DeMeo,Victoria Attaya,Amanda Okpoebo,Yuan Liu,Eric Gauthier,Harold J. Burstein,Meredith M. Regan,Sara M. Tolaney
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (5_Supplement): GS3-06 被引量:35
标识
DOI:10.1158/1538-7445.sabcs22-gs3-06
摘要

Abstract Background CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have a well-established role in the management of hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). The benefit of continuing CDK4/6i beyond progression in combination with a different ET has not been confirmed. Preclinical data suggest synergy between CDK4/6i and PD-L1 inhibition. The PACE trial prospectively evaluates whether continuation of the CKD4/6i palbociclib beyond progression on prior CDK4/6i and aromatase inhibitor (AI), with a change in ET to fulvestrant, improves outcomes beyond change to fulvestrant alone, as well as explores the activity of the palbociclib, fulvestrant, and avelumab triplet. Methods PACE is a multicenter randomized open-label investigator-initiated phase II trial, open at 11 U.S. sites. Eligible patients (pts) had HR+/HER2- evaluable MBC with prior progression on AI and any CDK4/6i after > 6 months (mo) of therapy in the MBC setting, or during/within 12 mo in the adjuvant setting, with no more than 1 prior line of chemotherapy for MBC. Pts were randomized 1:2:1 to fulvestrant alone (F); fulvestrant and palbociclib (F+P); or fulvestrant, palbociclib, avelumab (F+P+A), with tumor assessments every 8 weeks. Blood for circulating tumor DNA (ctDNA) analysis was collected at baseline, at times of tumor assessments, and at progression. The primary objective was to evaluate progression-free survival (PFS) with F+P vs F; secondary objectives included PFS with F+P+A vs F, objective response rate (ORR) in all arms, and safety. A sample size of 220 patients was planned to provide 80% power to detect an improvement in PFS with HR 0.6154 with F+P vs F (6.5 vs 4 mo; α(1)=0.05). Results A total of 220 pts were randomized from 9/2017-2/2022 (F: n=55, F+P: n=111, F+P+A: n=54); median age 57 years (range 25-83), 85% non-Hispanic (7.7% non-Hispanic black), 8.6% Hispanic, 6.4% unknown. 40% had de novo MBC, 60% had visceral disease, and 14% bone-only disease. 16% had 1 prior line of chemotherapy for MBC, 90% had received prior palbociclib, 4.5% ribociclib, 4.1% abemaciclib, 1.4% palbociclib and ribociclib. Pts entered the trial after a median 19 mo of prior CDK4/6i plus AI (interquartile range 12-31 mo). A total of 10 (5%) pts received protocol therapy as first line ET for MBC, 169 (77%) as second line, and 41 (17%) as beyond second line. 88% entered the trial directly after progression on CDK4/6i. After a median follow-up of 24 mo, 18 pts remained on protocol treatment. PFS was not improved with F+P vs F (median 4.6 vs 4.8 mo; HR=1.11, 90% CI 0.79-1.55; 2-sided p=0.62). Median PFS was 8.1 mo with F+P+A (HR=0.75 vs F, 90% CI 0.50-1.12; 2-sided p=0.23). ORR was 7.3% (90%CI 1.5-13.0) with F, 9.0% F+P (4.5-13.5%) and 13.0% F+P+A (5.4-20.5%). No new safety signals have been observed. Analysis of ctDNA panel sequencing encompassing 70 genes from 184 baseline samples, including correlation with known and hypothesized resistance genes, will be presented. Conclusions For ER+/HER2- breast cancer, combining palbociclib with fulvestrant beyond progression on prior CDK4/6i and AI did not significantly improve PFS compared with using fulvestrant alone. The observed longer PFS when a PD-L1 inhibitor was added to fulvestrant plus palbociclib is an intriguing signal in this ER+ population. Translational studies of blood and tumor tissue are ongoing and will be presented. Citation Format: Erica L. Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D. Miller, Trevor Jolly, Elizabeth Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Natalie Sinclair, Meredith Faggen, Caroline Block, Naomi Ko, Ann Partridge, Wendy Y. Chen, Michelle K. DeMeo, Victoria Attaya, Amanda Okpoebo, Yuan Liu, Eric Gauthier, Harold Burstein, Meredith Regan, Sara Tolaney. GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr GS3-06.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
忧郁的涵雁完成签到 ,获得积分10
4秒前
31秒前
34秒前
lingrong发布了新的文献求助10
38秒前
M.发布了新的文献求助10
39秒前
M.完成签到,获得积分10
44秒前
46秒前
酷波er的应助被lingrong采纳,获得10
49秒前
佳言2009完成签到 ,获得积分10
55秒前
负责的初柔完成签到 ,获得积分10
1分钟前
科研通AI6.4的应助被张阳采纳,获得10
1分钟前
1分钟前
1分钟前
yyzc6162发布了新的文献求助10
1分钟前
慕容杏子完成签到 ,获得积分10
1分钟前
1分钟前
MchemG的应助被科研通管家采纳,获得30
1分钟前
MchemG的应助被科研通管家采纳,获得30
1分钟前
1分钟前
1分钟前
清爽友蕊发布了新的文献求助10
1分钟前
张阳发布了新的文献求助10
1分钟前
在水一方的应助被amiee采纳,获得10
1分钟前
1分钟前
2分钟前
yyzc6162完成签到,获得积分10
2分钟前
amiee发布了新的文献求助10
2分钟前
忧虑的如雪完成签到,获得积分10
2分钟前
完美世界的应助被清爽友蕊采纳,获得10
2分钟前
犹豫擎苍完成签到,获得积分10
2分钟前
adefgv完成签到,获得积分10
3分钟前
3分钟前
fhjg完成签到,获得积分10
3分钟前
3分钟前
jtk完成签到,获得积分10
3分钟前
pwn完成签到,获得积分10
3分钟前
3分钟前
3分钟前
彭于晏的应助被科研通管家采纳,获得10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190127
求助须知:如何正确求助?哪些是违规求助? 9577239
关于积分的说明 21852194
捐赠科研通 7788458
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2560003
邀请新用户注册赠送积分活动 2482880